Charmacy Pharmaceutical Reports Record Net Profit of RMB32 Million for 11-Month Period
December 30, 2022
Trending News ☀️
Charmacy Pharmaceutical ($SEHK:02289) is a leading Chinese pharmaceutical company that is listed on the Shenzhen Stock Exchange. It specializes in providing a wide range of innovative and quality drugs, health products and medical equipment to both domestic and international customers. Charmacy Pharmaceutical has reported a record net profit of RMB32 million for the period. The company attributes its success to the strong performance of its core product lines, which have seen robust growth in sales in both domestic and international markets. The company has also been able to expand its product portfolio by introducing new products, which has helped it to gain a competitive edge in the market. The company’s aggressive marketing campaigns have also played a role in its success. Charmacy Pharmaceutical has managed to reach out to a wider customer base through the use of digital marketing and advertising campaigns.
This has enabled the company to gain valuable insights into customer preferences, which has helped it to design more attractive and effective product offerings. The company has also worked hard to maintain a healthy balance sheet by controlling costs, managing debt, and investing in research and development. This has enabled it to remain competitive in the market, and also helped it to maximize its profits. The company’s success is due to its focus on innovation, marketing, and cost control. With such a strong performance, the company looks set to continue its success into 2021.
Stock Price
This news has been met with mostly positive sentiment and has been reflected in the stock markets. On Wednesday, CHARMACY PHARMACEUTICAL stock opened at HK$7.0 and closed at HK$7.0, leaving it unchanged over the day. The company has attributed this success to its diversified product portfolio, which includes prescription drugs, OTC medications, and herbal medicines. Charmacy Pharmaceutical has also invested heavily in research and development, which has helped them to stay ahead of the competition. Charmacy Pharmaceutical has also benefited from its strong partnerships with other companies in the industry. This has enabled them to gain access to new markets and technologies, allowing them to expand their product offerings and reach more customers.
Its strategic partnerships have also helped the company to reduce costs and increase efficiency. Its diversified product portfolio and strategic partnerships have enabled it to remain competitive in the global market. The company is now well-positioned to continue its growth and increase its market share in the years to come. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Charmacy Pharmaceutical. More…
| Total Revenues | Net Income | Net Margin |
| 3.69k | 17.83 | 0.5% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Charmacy Pharmaceutical. More…
| Operations | Investing | Financing |
| 58.82 | -4.89 | -21.14 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Charmacy Pharmaceutical. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 2.65k | 2.12k | 4.86 |
Key Ratios Snapshot
Some of the financial key ratios for Charmacy Pharmaceutical are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 0.6% | -9.6% | 1.7% |
| FCF Margin | ROE | ROA |
| 1.4% | 7.6% | 1.5% |
VI Analysis
Charmacy Pharmaceuticals is a medium-risk investment according to the VI Risk Rating. This rating is based on the company’s fundamentals and reflects its long-term potential. By using the VI App, investors can quickly and easily assess how risky an investment may be. The app provides warnings for any potential risks in the income sheet and balance sheet, so investors can make informed decisions about their investments. The app also allows for a more detailed analysis of the company’s financials. It can provide a look at the company’s short-term and long-term debt, cash flow, and liquidity. Investors can also use the app to compare the company’s past performance with that of its competitors. This gives them an idea of whether the company has been able to keep up with industry trends and whether it has potential for future growth. The VI App can also provide investors with a variety of metrics that they can use to assess the company’s performance. This includes metrics such as return on equity, return on capital employed, and cash flow coverage ratio. By using these metrics, investors can get a better idea of how the company is doing financially and whether it is a worthy investment. Overall, the VI App makes it easy for investors to assess the risk associated with Charmacy Pharmaceuticals and make informed decisions about their investments. By using this app, investors can gain valuable insights into the company’s finances, compare its performance to that of its competitors, and get a better understanding of its long-term potential. More…
VI Peers
Charmacy Pharmaceutical Co Ltd is one of the leading pharmaceutical companies in China, providing quality medicines and healthcare solutions to its customers. They face stiff competition from other major players in the industry such as China Medicine Corp, China National Accord Medicines Corp Ltd and Sigma Healthcare Ltd. All these companies strive to provide safe and effective medicines as well as innovative solutions for better healthcare.
– China Medicine Corp ($OTCPK:CHME)
China Medicine Corp is a publicly traded pharmaceutical company that specializes in the development, production, and marketing of traditional Chinese medicine and modern pharmaceuticals. The company has a market cap of 284.54k as of 2022 and a Return on Equity of 20.97%. The market cap of China Medicine Corp indicates the company’s size, value, and financial performance. The Return on Equity measures the efficiency of the company’s management in turning stockholder investments into profits. This high return on equity demonstrates that the company is managed effectively and efficiently.
– China National Accord Medicines Corp Ltd ($SZSE:000028)
National Accord Medicines Corp Ltd, based in China, is a leading pharmaceutical company focused on the research and development, production, and marketing of pharmaceutical products. As of 2022, the company has a market capitalization of 13.45 billion, making it one of the largest pharmaceutical companies in the country. The company has also achieved a return on equity of 8.92%, which is relatively high compared to its peers. This suggests that the company is managing its investments efficiently and is able to generate high returns from its investments. National Accord Medicines Corp Ltd has a strong presence in both the domestic and international markets, providing quality and affordable medicines to meet the needs of its customers.
– Sigma Healthcare Ltd ($ASX:SIG)
Sigma Healthcare Ltd is a healthcare provider and pharmacy group in Australia, operating a national network of over 600 pharmacies. The company is listed on the Australian Securities Exchange and has a market cap of 646.16M as of 2022. It has a Return on Equity (ROE) of 0.46%, which is relatively low compared to other companies in the industry. This indicates that the company may not be performing as well as its peers. Nevertheless, Sigma Healthcare remains a dominant player in the Australian healthcare sector.
Summary
Charmacy Pharmaceuticals reported a record 11-month net profit of RMB32 million, indicating a positive outlook for investors. With strong financial performance, the company has demonstrated its ability to generate consistent growth, making it an attractive opportunity for investors. The stock has seen a steady rise in value over the past year, reflecting investor confidence in the company. With a stable market and strong fundamentals, Charmacy Pharmaceuticals is poised to be a profitable investment in the coming months.
Related Posts
Recent Posts
